News & Events

  • SACHS Associates 2018

    When: Oct. 4th, 2018 to Oct. 5th, 2018
    Where: Basel, Switzerland

    Anima Biotech has participated and presented at the 18th Annual Biotech in Europe Forum.
    In Addition, Yochi Slonim, Anima Biotech co-founder & CEO, co-chaired the Platform Technologies & Novel Therapeutics Panel.
    The Sachs Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry.

    Visit the conference website »

  • Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

    When: Jul. 23rd, 2018

    Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.
    The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration.

    Under the terms of the agreement, Anima will receive $30 million in upfront payments and $14 million in research funding. Anima is eligible to receive up to $1.05 billion if all future development and commercial milestones are achieved. Anima will additionally be entitled to low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

    “We are excited to collaborate with Lilly in the discovery of new drugs for some of the world’s most challenging diseases.  Small molecule drugs work by binding to disease-causing proteins to modify their chemical activity but most proteins lack accessible binding sites and as result, many diseases remain without effective treatments. Anima’s Translation Control Therapeutics platform is a new strategy against these undruggable target proteins. Rather than attempt to drug them after they are already made, we discover drugs that work one step before, by inhibiting (decreasing) or increasing the actual production by ribosomes of those proteins. This different approach is based on our novel science and patented technology and we believe it can lead to many new drugs” said Yochi Slonim, Anima Biotech’s co-founder and CEO.

    Download Press Release in English »
    Download Press Release in Hebrew »

  • International tRNA Conference 2018

    When: Sep. 23rd, 2018 to Sep. 27th, 2018
    Where: Strasbourg, France

    Anima Biotech has participated and presented at the 27th International tRNA Conference “tRNA at the crossroad”.

    This event brings together researchers from around the world studying the many aspects of tRNA biology.

    Visit the conference website »

  • Translational Control 2018

    When: Sep. 4th, 2018 to Sep. 8th, 2018
    Where: Cold Spring Harbor, USA

    Anima Biotech has participated and presented at the sixteenth conference on Translational Control to be held at Cold Spring Harbor Laboratory.

    Visit the conference website »

  • 2018 BIO International Convention

    When: Jun. 4th, 2018 to Jun. 7th, 2018
    Where: Boston, USA

    Anima Biotech has participated and presented at the 2018 BIO International Convention.

    The conference is hosted by the Biotechnology Innovation Organization who represents over 1,100 biotech companies, academic institutions, state biotech centers and related organizations across the US and over 30 other nations.

    Visit the convention website »

  • 2018 Biotech Investment Showcase

    When: May. 22nd, 2018 to May. 23rd, 2018
    Where: London, United Kingdom

    Anima Biotech has participated and presented at the BIOTECH INVESTMENT SHOWCASE organized by the Oxford Global Conferences Ltd.

    The 2018 Biotech Investment showcase is the UK and Europe’s most focused and leading-edge funding, investment and partnering forum in the biotech sector, hosting over 200 attendees.

    Visit the conference website »

  • BIOMED 2018

    When: May. 15th, 2018 to May. 17th, 2018
    Where: Tel-Aviv, Israel

    Anima Biotech has participated at the 17th MIXiii-BIOMED 2018 Conference and Exhibition.

    As the leading event of Israel’s life sciences industry, MIXiii-BIOMED has positioned itself throughout the years as the main annual meeting place for players of Israel’s healthcare industry with their colleagues from around the globe.

    Visit the conference website »

  • Genesis Drug Discovery 2018

    When: May. 10th, 2018 to May. 11th, 2018
    Where: Barcelona, Spain

    Anima Biotech has participated and presented at the 2nd annual Genesis Drug Discovery

    Genesis Drug Discovery (GDD) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange that will give all the participants the opportunity to share their experiences, foster collaborations across industry and academia and evaluate emerging technologies across the globe.

    Visit the conference website »

  • BIO-Europe Spring 2018

    When: Mar. 12th, 2018 to Mar. 14th, 2018
    Where: Amsterdam, The Netherlands

    Anima Biotech has participated and presented at BIO-Europe Spring 2018.

    With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.

    Visit the conference website »

  • SACHS Associates 2018

    When: Feb. 26th, 2018 to Feb. 27th, 2018
    Where: Zurich, Switzerland

    Anima Biotech has participated and presented at the 11th Annual  European Life Sciences CEO Forum.

    Back for its 11th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2018 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. The Forum also features keynote speeches by KOL, about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. There is also a focus on early-stage innovation and an elevator session with up 20 presentations by start-ups from BioMed and Digital Health.

    Visit the conference website »

Pages